Try a new search

Format these results:

Searched for:



Total Results:


Novel use of endoscopically placed fiducial markers for targeted radiation therapy of colonic lymphomas

Gurvits, Grigoriy E; Marsano, Joseph; Kobrinsky, Boris; Shin, Samuel; Sanfilippo, Nicholas; Volkov, Dmitri
Non-Hodgkin's lymphomas (NHL) are an important variety of gastrointestinal tumors with increasing incidence and prevalence. Traditional management of NHL with chemotherapy is challenging and expanding evidence points to significant tumor response to radiation therapy (RT). However, there exists a wide range of radiation-related toxicities. Optimization of exact tumor marking coupled with minimization of the radius of radiation delivery is essential to increase patient's tolerance and decrease side effects of the treatment. We report our experience with mantle cell lymphoma of the colon treated with precision RT after endoscopic placement of resolution clips in a "shooting target" fashion in a patient who failed conventional chemotherapy. Fourteen months after completion of RT, the patient remains in complete remission.
PMID: 25330785
ISSN: 1108-7471
CID: 1316162

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity

Kobrinsky, B; Joseph, S O; Muggia, F; Liebes, L; Beric, A; Malankar, A; Ivy, P; Hochster, H
PURPOSE: The potential synergy of modulating platinum-induced DNA damage by combining the proteasome inhibitor bortezomib with oxaliplatin was studied in patients with solid tumors, with special attention to avoidance of cumulative neurotoxicity (NT). PATIENTS AND METHODS: In a 3 + 3 dose escalation design, patients received bortezomib at 1.0-1.5 mg/m(2) on days 1 and 4 and oxaliplatin at 60-85 mg/m(2) on day 1 of a 14-day cycle. NT assessments were performed at the start of every two cycles. Oxaliplatin pharmacokinetics (PK) were determined pre- and post-bortezomib. RESULTS: Thirty patients were enrolled with 25 (11 men, 14 women) fully evaluable for NT assessments at cycle 2. The median age was 56 years (range 35-74 years); median number of cycles received 2 (range 1-10). At dose levels 2-5 (B 1.3 mg/m(2)), patients manifested NT grades 3 and 4 at a median 3.4 cycles (range 2-9 cycles): 3 had ataxia (one also with sensory neuropathy or neurogenic hypotension, respectively) and 3 had just sensory neuropathy. A 6th dose-level reducing bortezomib to 1.0 mg/m(2) with oxaliplatin 85 mg/m(2)) was explored and no NT or dose limiting toxicities were noted among 7 evaluable patients (5 receiving two or more cycles). Four patients experienced a partial response-one with platinum-resistant ovarian cancer, another with gastroesophageal cancer, another with ampulla of Vater carcinoma, and a patient with cholangiocarcinoma. PK studies at dose levels 1 and 2 showed greater mean ultrafiltrable platinum when oxaliplatin was dosed after bortezomib. CONCLUSIONS: Bortezomib 1.0 mg/m(2) x 2 every 14 days combines safely with oxaliplatin. At higher doses, cumulative NT (i.e., cerebellar signs and sensory neuropathy) occurs at an accelerated pace perhaps from a PK interaction.
PMID: 24048674
ISSN: 0344-5704
CID: 598422

Cardiac Effects of Cancer Therapy

Chapter by: Zheng, H; Kobrinsky, B; Katz, S; Speyer, JL
in: Abeloff's clinical oncology by
Philadelphia, PA : Churchill Livingstone/Elsevier, c2013
pp. 858-873.e5
ISBN: 9780323222112
CID: 1843162

Case report: thymic carcinoma metastatic to small bowel

Kobrinsky, Boris; Khaykis, Inessa; Hill, Day; Petrovic, Lydia; Yee, Herman; Chandra, Anurag; Diehl, David L
PMID: 21892321
ISSN: 1177-9314
CID: 137078

Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal Doxorubicin

Kobrinsky, Boris; Andreopoulou, Eleni; Mourtzikos, Karen; Muggia, Franco
PMID: 21892319
ISSN: 1177-9314
CID: 161233